Target intelligence / Profile preview

Myotonin-protein kinase (DMPK)

Target
DMPK
Molecular classification
Enzyme, Protein kinase, Serine/threonine-protein kinase, Non-receptor serine/threonine protein kinase
01

Overview

Myotonin-protein kinase (DMPK) is a non-receptor serine/threonine protein kinase primarily expressed in skeletal, cardiac, and smooth muscle tissues, where it plays a critical role in maintaining muscle structure, ion homeostasis, and cardiac conduction. The DMPK gene is the genetic locus for myotonic dystrophy type 1 (DM1), an autosomal dominant neuromuscular disorder caused by an abnormal expansion of CTG trinucleotide repeats in the 3' untranslated region (3' UTR) of the gene. This expansion leads to the transcription of toxic mutant DMPK mRNAs containing long CUG repeats, which accumulate in nuclear foci and sequester essential RNA-binding proteins, particularly muscleblind-like (MBNL) splicing factors. The resulting loss of free MBNL proteins causes widespread alternative splicing defects (spliceopathy) that drive the clinical manifestations of DM1, including myotonia, muscle wasting, and cardiac arrhythmias. Therapeutic strategies targeting DMPK focus on reducing the levels of these toxic transcripts using RNA-targeted modalities, such as antibody-oligonucleotide conjugates (AOCs) like delpacibart etedesiran (del-desiran) and zeleciment basivarsen (z-basivarsen), which deliver small interfering RNAs (siRNAs) or antisense oligonucleotides (ASOs) to degrade mutant DMPK mRNA and restore normal splicing.

Other names
Dystrophia myotonica protein kinaseDM1 protein kinaseDM-kinaseDMKMDPKMT-PKMyotonic dystrophy protein kinase
02

Mechanism of action

siRNA-mediated degradation of DMPK mRNA, Antisense oligonucleotide (ASO)-mediated RNase H cleavage of DMPK mRNA, and steric blocking of CUG repeats on DMPK mRNA

03

Biological functions

Signal transductionMuscle homeostasisCytoskeletal dynamicsIon homeostasisMyocyte differentiationCardiac contractilitySynaptic plasticity
04

Disease associations

Myotonic dystrophy type 1Neuromuscular diseaseCardiovascular diseaseCataractMuscle wasting
05

Safety considerations

Potential for cardiac conduction abnormalities or skeletal myopathy due to severe loss of physiological DMPK proteinInfusion-related reactionsAnemiaThalamic infarction (noted as a serious adverse event in clinical trials of del-desiran)Off-target effects of oligonucleotidesNuclease degradation and tissue-specific accumulation challenges
06

Interacting drugs

Delpacibart etedesiran (del-desiran, AOC 1001)

4 more in the full profile.

07

Biomarkers

DMPK mRNA levelsAlternative splicing patterns (spliceopathy correction)Inferred intracellular MBNL1 levelsVideo hand opening time (vHOT)Quantitative muscle testing (QMT)

Beyond the preview

Go deeper on Myotonin-protein kinase (DMPK).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myotonin-protein kinase (DMPK).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call